Treatment of IgA nephropathy: An update;El tratamiento de nefropatía iga: una actualización

Annals of Pharmacotherapy

Volumn 45, Issue 10, 2011, Pages 1284-1296

  Rosselli, Jennifer L ^a,b   Thacker, Stacey M ^a   Karpinski, Julie P ^c,d   Petkewicz, Katherine A ^e  

^a SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

^b Southern Illinois Healthcare Foundation   (United States)

^c Department of Pharmaceutical Sciences   (United States)

^d FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

^e Clinical Pharmacist Specialist   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin ii receptor blockers; Anticoagulants; Antiplatelets; Azathioprine; Berger's disease; Calcitriol; Corticosteroids; Cyclophosphamide; Cyclosporine; Fish oil; Hydroxymethylglutaryl coa reductase inhibitors; Immunoglobulin a nephropathy; Infliximab; Leflunomide; Mycophenolate mofetil; Vitamin e

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CALCITRIOL; CILAZAPRIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DILAZEP; DIPYRIDAMOLE; ENALAPRIL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; LOSARTAN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEGA 3 FATTY ACID; PREDNISONE; TRIMETAZIDINE; VALSARTAN; WARFARIN;

ADD ON THERAPY; ANEMIA; ANKYLOSING SPONDYLITIS; BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; GLUTEN FREE DIET; HUMAN; HYPERCALCEMIA; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MEDICAL RECORD REVIEW; MEDLINE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANGIOTENSINS; ANIMALS; COMBINED MODALITY THERAPY; GLOMERULONEPHRITIS, IGA; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; IMMUNOSUPPRESSION; KIDNEY FAILURE, CHRONIC;

EID: 80053983075     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q122     Document Type: Review

References (83)

1. Mubarak M. IgA nephropathy: an update on pathogenesis and classification. J Coll Physicians Surg Pak 2011;21:230-3.
2. Donadio JV, Grande JP. Immunoglobulin A nephropathy: a clinical perspective. J Am Soc Nephrol 1997;8:1324-32.
3. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002;347:738-48.
4. Davin JC, Weening JJ. Berger disease: thirty years later. Eur J Pediatr 1999;158:437-43.
5. Glassock RJ. IgA nephropathy: challenges and opportunities. Cleve Clin J Med 2008;75:569-76.
6. Laville M, Almartine E. Treatment options for IgA nephropathy in adults: a proposal for evidence-based strategy. Nephrol Dial Transplant 2004;19:1947-51. DOI 10.1093/ndt/gfh309
7. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000;36:227-37.
8. Nolin L, Courteau M. Management of IgA nephropathy: evidence-based recommendations. Kidney Int Suppl 1999;70:S56-62. DOI 10.1046/j.1523-1755.1999.07008.x
9. Eitner F, Ackermann D, Hilgers R, Floege J. Supportive versus immunosuppressive therapy of progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol. J Nephrol 2008;21:284-9.
10. Xie Y, Chen X, Nishi S, Narita I, Gejyo F. Relationship between tonsil and IgA nephropathy as well as indications of tonsillectomy. Kidney Int 2004;65:1135-1144.
11. Xie Y, Nishi S, Ueno M, et al. The efficacy of tonsillectomy in long-term renal survival in patients with IgAN. Kidney Int 2003;63:1861-1870.
12. Lai KN. Future directions in the treatment of IgA nephropathy. Nephron 2002;92:263-270.
13. Nagy J, Scott H, Brandtzaeg P. Antibodies to dietary antigens in IgA nephropathy. Clin Nephrol 1988;29:275-9.
14. Coppo R, Basolo B, Rollino C, Roccatello D, Martina G, Amore A. Dietary gluten and primary IgA nephropathy. N Engl J Med 1986;315:1167-8.
15. Lau AH. Glomerulonephritis. In: Dipiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: a pathophysiologic approach. 5th ed. New York: McGraw-Hill, 2002:927-8.
16. Reid S, Cawthon PM, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev 2011;(3):CD003962. DOI 10.1002/14651858.CD003962.pub2
17. Chen J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials. Int J Clin Pract 2009;63:880-8. DOI 10.111/j.1742-1241.2009.02038.x
18. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandex E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003;14:1578-83. DOI 10.1097/01.ASN.0000068460.37369.DC
19. Li PK, Leung CB, Chow KM, et al. Hong Kong Study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006;47:751-760. DOI 10.1053/j.ajkd.2006.01.017
20. Woo KT, Lau YK, Wong K, Chiang GS. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int 2000;58:2485-91.
21. Woo KT, Lau YK, Chan CM, et al. ATRA therapy restores normal renal function and renal reserve and prevents renal failure. Ann Acad Med Singapore 2005;34:52-9.
22. Woo KT, Chan CM, Tan HK, et al. Beneficial effects of high-dose losartan in IgA nephritis. Clinical Nephrology 2009;71:617-24.
23. Horita Y, Tadokoro M, Taura K, et al. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertens Res 2004;27:963-70.
24. Kim M, Song JH, Suh JH, Lee SW, Kim GA. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy. Yonsei Med J 2003;44:463-72.
25. Russo D, Pisani A, Balletta MM, et al. Additive anti-proteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999;33:851-6.
26. Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.
27. Dillon JJ. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 1997;8:1739-44.
28. Donadio JV, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. J Am Soc Nephrol 1999;10:1772-7.
29. Donadio JV, Bergstralh EF, Offord DP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. N Engl J Med 1994;331:1194-9.
30. Hamazaki T, Tateno S, Shishido H. Eicosapentaenoic acid and IgA nephropathy. Lancet 1984;1:1017-8.
31. Donadio JV, Larson TS, Bergstralh EJ, Grande JP. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 2001;12:791-9.
32. Alexopoulos E, Stangou M, Pantzaki A, Kirmizis D, Memmos D. Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a "very low dose" regimen. Renal Failure 2004;26:453-9. DOI 10.1081/JDI-200026763
33. Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol Dial Transplant 2009;24:156-60. DOI 10.1093/ndt/gfn454
34. Kano K, Nishikura K, Yamada Y, Arisaka O. Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria. Clinical Nephrology 2003;60:85-9.
35. Buemi M, Allegra A, Corica F, et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 2000;67:427-31. DOI 10.1067/mcp.2000.105330
36. Woo KT, Edmondson RP, Yap HK, et al. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clin Nephrol. 1987;27:56-64.
37. Woo KT, Chiang GS, Yap HK, Lim CH. Controlled therapeutic trial of IgA nephritis with follow-up renal biopsies. Ann Acad Med Singapore 1988;17:226-31.
38. Walker RG, Yu SH, Owen JE, Kincaid-Smith P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin Nephrol 1990;34:103-7.
39. Lee GSL, Choong HL, Chiang GSC, Woo KT. Three-year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment. Nephrology 1997;3:117-21. DOI 10.1111/j.1440-1797.1997.tb00201.x
40. Ishii T, Kawamura T, Tsuboi N, Ogura M, Utsunomiya Y, Hosoya T. Prospective trial of combined therapy with heparin/warfarin and reninangiotensin system inhibitors in progressive IgA nephropathy. Contrib Nephrol 2007;157:114-9.
41. Yoshikawa N, Ito H, Sakai T, et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 1999;10:101-9.
42. Yoshikawa N, Honda M, Iijima K, et al. Japanese Pediatric IgA Nephropathy Treatment Study Group. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 2006;1:511-7. DOI 10.2215/CJN.01120905
43. Taji Y, Kuwahara T, Shikata S, Morimoto T. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin Exp Nephrol 2006;10:268-73. DOI 10.1007/s10157-006-0433-8
44. Thomas M. Specific management of IgA nephropathy: role of triple therapy and cytotoxic therapy. Nephrology 2006;11:S141-5. DOI 10.1111/j.1440-1797.2006.00629.x
45. Woo KT, Lee GS, Pall AA. Dipyridamole and low-dose warfarin without cyclophosphamide in the management of IgA nephropathy. Kidney Int 2000;57:348-9. DOI 10.1046/j.1523-1755.2000.00843.x
46. Floege J, Eitner F. Immune modulating therapy for IgA nephropathy: rationale and evidence. Semin Nephrol 2008;28:38-47.
47. Samuels JA, Strippoli GFM, Craig JC, Schena FP, Molony DA. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 2003;(4):CD003965. DOI 10.1002/14651858.CD003965
48. Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999;353:883-7.
49. Samuels JA, Strippoli GF, Craig JC, et al. Immunosuppresive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology 2004:9:177-85.
50. Zhou YH, Tang LG, Guo SL, et al. Steroids in the treatment of IgA nephropathy to the improvement of renal survival: a systematic review and meta-analysis. PLoS ONE 2011;6:e18788. DOI 10.1371/journal.pone.0018788
51. Katafuchi R, Ikeda K, Mizumasa T, et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis 2003;41:972-83. DOI 10.1016/S0272-6386%2803%2900194-x
52. Koike M, Takei T, Uchida K, et al. Clinical assessment of low-dose steroid therapy for patients with IgA nephropathy: a prospective study in a single center. Clin Exp Nephrol 2008;12:250-5. DOI 10.1007/s10157-008-0036-7
53. Manno C, Torres D, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009;24:3694-701. DOI 10.1093/ndt/gfp356
54. Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 2009;53: 26-32. DOI 10.1053/j.ajkd.2008.07.029
55. Horita Y, Tadokoro M, Taura K, et al. Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy. Ren Fail 2007;29:441-6. DOI 10.1080/08860220701260511
56. Tang S, Tang A, Wong S, et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 2010;77:543-9. DOI 10.1038/ki.2009.499
57. Tan CH, Loh PT, Yang WS, Chan CM. Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review. Singapore Med J 2008;49:780-5.
58. Xu G, Tu W, Jiang D, Xu C. Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis. Am J Nephrol 2009;29:362-7. DOI 10.1159/000168483
59. Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double- blind randomized controlled trial. Nephrol Dial Transplant 2005;20: 2139-45. DOI 10.1093/ndt/gjh974
60. Appel GB, Radhakrishnan J, Ginzler EM. Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation 2005;80:265-271. DOI 10.1097/01.tp.0000186389.19911.9c
61. Rasche FM, Keller F, von Muller L, Czock D, Lepper PM. Sequential immunosuppressive therapy in progressive IgA nephropathy. Contrib Nephrol 2007;157:109-13.
62. Sahin GM, Sahin S, Kantarci G, Ergin H. Mycophenolate mofetil treatment for therapy-resistant glomerulopathies. Nephrology 2007;12:285-8. DOI 10.1111/j.1440-1797.2006.00763.x
63. Dal CA, Amore A, Barbano G, et al. One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomized controlled study. J Nephrol 2005;18:136-140.
64. Hogg RJ, Wyatt RJ; Scientific Planning Committee of the North American IgA Nephropathy Study. A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616]. BMC Nephrol 2004;5:3.
65. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13:142-8.
66. Bazzi C, Rizza V, Raimondi S, et al. In crescentic IgA nephropathy, fractional excretion of IgG in combination with nephron loss is the best predictor of progression and responsiveness to immunosuppression. Clin J Am Soc Nephrol 2009;4:929-35. DOI 10.2215/CJN.05711108
67. Mitsuiki K, Harada A, Okura T, Higaki J. Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide. Clin Exp Nephrol 2007;11:297-303. DOI 10.1007/s10157-007-0497-0
68. Oshima S, Kawamura O. Long-term follow-up of patients with IgA nephropathy treated with prednisolone and cyclophosphamide therapy. Clin Exp Nephrol 2008;12:264-9. DOI 10.1007/s10157-008-0045-650.
69. Woo KT, Lee GS, Lau YK, Chiang GS, Lim CH. Effects of triple therapy in IgA nephritis: a follow-up study 5 years later. Clin Nephrol 1991;36:60-6.
70. Lai KN, Lai FM, Li PK, Vallance-Own J. Cyclosporin treatment of IgA nephropathy: a short-term controlled trial. Br Med J 1987;295:1165-8.
71. Chabova V, Tesar V, Zabka J, et al. Long term treatment of IgA nephropathy with cyclosporine A. Ren Fail 2000;22:55-62.
72. Pozzi C, Andrulli S, Pani A, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 2010;21:1783-90.
73. Goumenos DS, Davlouros P, El Nahas AM, et al. Prednisolone and azathioprine in IgA nephropathy-a ten-year follow-up study. Nephron Clin Pract 2003;93:c58-68. DOI 10.1159/000068522
74. Stangou M, Ekonomidou D, Giamalis P, et al. Steroids and azathioprine in the treatment of IgA nephropathy. Clin Exp Nephrol 2011;15:373-80. DOI 10.1007/s10157-011-0415-3
75. Lou T, Wang C, Chen Z, et al. Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy. Nephrology 2006;11:113-6. DOI 10.1111/j.1440-1797.2006.00547.x
76. Liu XW, Li DM, Xu GS, Sun SR. Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephritic syndrome. Int J Clin Pharmacol Ther 2010;48:509-13.
77. Chan JC, Mahan JD, Trachtman H, et al. Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study. Pediatr Nephrol 2003;18:1015-9. DOI 10.1007/s00467-003-1205-2
78. Thomas M. Specific management of IgA nephropathy: role of cyclosporin and other therapies. Nephrology 2006;11:S149-53. DOI 10.1111/j.1440-1797.2006.00631.x
79. Sakellariou GT, Vounotrypidis P, Berberidis C. Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy. Clin Rheumatol 2007;26:1132-3. DOI 10.1007/s10067-006-0422-z
80. Jacquet A, Francois H, Frangie C, et al. IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy. Nephrol Dial Transplant 2009;24:3540-2. DOI 10.1093/ndt/gfp314
81. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis 2008;51:724-731. DOI 10.1053/j.ajkd.2007.12.038
82. Rasche FM, Keller F, Lepper PM, et al. High-dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy: a long-term follow-up. Clin Exp Immunol 2006;146: 47-53. DOI 10.1111/j.1365-2249.2006.03189.x
83. Rostoker G, Desvaux-Belghiti D, Pilatte Y, et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schönlein purpura. Ann Intern Med 1994;120:476-84.